Pulmonary and Cardiovascular Complications of Cancer Therapy

  • Matthew Volm
  • Howard Hochster
Chapter

Abstract

Pulmonary complications arising from antineoplastic drugs range from asymptomatic, mild abnormalities (detected by chest radiograph or pulmonary function tests) to fatal pulmonary fibrosis. The incidence and severity of pulmonary toxicity depend on the characteristics of the responsible drug as well as host factors. It is useful to consider three major syndromes that may result from the pharmacologic treatment of cancer: 1) acute drug reactions (usually hypersensitivity), 2) noncardiogenic pulmonary edema, and 3) interstitial pneumonitis/pulmonary fibrosis. Table 28–1 provides a list of the drugs associated with pulmonary complications [1].

Keywords

Advanced Breast Cancer Cardiac Toxicity Pulmonary Toxicity Vinca Alkaloid Noncardiogenic Pulmonary Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Twohig K, Matthay R: Pulmonary effects of cytotoxic agents otherthan bleomycin. Clin Chest Med 1990, 11: 31–54.PubMedGoogle Scholar
  2. 2.
    Aapro MS, Martin C, Hatty S: Gemcitabine: a safety review. Anti-Cancer Drugs 1998, 9: 191–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Pavlakis N, Bell DR, Millward MJ, et al.: Fatal pulmonary toxicity resulting from treatment with gemcitabine [see comments]. Cancer 1997, 80:286–291.PubMedCrossRefGoogle Scholar
  4. 4.
    Crooke S, Bradner W: Bleomycin: a review. JMed 1976, 7: 333–428.Google Scholar
  5. 5.
    Jules-Elysee K, White D: Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990, 11: 1–20.PubMedGoogle Scholar
  6. 6.
    Comis R: Bleomycin pulmonary toxicity: current status and future directions. Semin Onco1 1992, 19(suppl 5):64–70.Google Scholar
  7. 7.
    Comis R: Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990, 8: 765–767.PubMedGoogle Scholar
  8. 8.
    Lei K, Leung W, Johnson P: Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin’s lymphoma. BrJ Cancer 1994, 70: 1009–1013.CrossRefGoogle Scholar
  9. 9.
    Saxman S, Nichols C, Einhorn L: Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997, 111:657–660.PubMedCrossRefGoogle Scholar
  10. 10.
    Buzdar A, Legha S, Luna M, et al.: Pulmonary toxicity of mitomycin. Cancer 1980, 45:236–244.PubMedCrossRefGoogle Scholar
  11. 11.
    Weinstein A, Deiner-West M, Nelson D, et al.: Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep 1986, 70:943–946.PubMedGoogle Scholar
  12. 12.
    Gibson S, Comis R: The pulmonary toxicity of antineoplastic agents. Semin Onco11982 9:34–51.Google Scholar
  13. 13.
    Abdel-Razeq H, Overmoyer B, Pohlman B, et al.: Pulmonary toxicity of STAMP V preparative regimen in high-dose chemotherapy (HDC) and autologous bone marrow transplantation (ABMT) for breast cancer [abstract]. Proc Annu Meet Am Soc Clin Onco1 1997 16:100.Google Scholar
  14. 14.
    Rosiello R, Merrill W: Radiation-induced lung injury. Clin Chest Med 1990, 11:65–71.PubMedGoogle Scholar
  15. 15.
    Speyer J, Freedberg R: Clinical Oncology. New York: Churchill Livingstone, Inc.; 1995.Google Scholar
  16. 16.
    Trehu EG, Karp DD, Atkins MB: Possible myocardial toxicity associated with Interleukin-4 therapy. J Immunother 1993, 14:348–351.CrossRefGoogle Scholar
  17. 17.
    Von Hoff D, Layard M, Basa P, et al.: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979, 91:710–717.CrossRefGoogle Scholar
  18. 18.
    Von Hoff D, Rozencweig M, Layard M, et al.: Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am JMed 1977, 62:200–208.Google Scholar
  19. 19.
    Hochster H, Wasserheit C, Speyer J: Cardiotoxicity and cardioprotection during chemotherapy. Curr Opinion Oncol 1995, 7:304–309.CrossRefGoogle Scholar
  20. 20.
    Gianni L, Myers C: The role of free radical formation in the cardiotoxicity of anthracycline. In Cancer Treatment and the Heart. Edited by Muggia F, Green M, Speyer J. Baltimore: The Johns Hopkins University Press; 1992:9–46.Google Scholar
  21. 21.
    Bristow M, Mason J, Billingham M, et al.: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981, 102:709–718.PubMedCrossRefGoogle Scholar
  22. 22.
    Speyer J, Green M, Zeleniuch-Jacquotte A, et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992, 10:117–127.PubMedGoogle Scholar
  23. 23.
    Swain S, Whaley F, Gerber M, et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Onco1 1997, 15:1318–1332.Google Scholar
  24. 24.
    Wexler L, Andrich M, Venzon D, et al.: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Onco1 1996, 14:362–372.Google Scholar
  25. 25.
    Billingham M, Mason J, Bristow M, et al.: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865–872.PubMedGoogle Scholar
  26. 26.
    Gianni L, Munzone E, Capri G, et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study [abstract]. J Clin Oncol 1995, 13:2688–2699.PubMedGoogle Scholar
  27. 27.
    Dombernowsky P, Gehl J, Boesgaard M, et al.: Doxorubicin and paclitaxel: a highly active combination in the treatment of metastatic breast cancer. Semin Onco1 1996, 23 (suppl 11):23–27.Google Scholar
  28. 28.
    Gianni L, Bigano L, Locatelli A, et al.: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Onco1 1997, 15:1906–1915.Google Scholar
  29. 29.
    Holmes FA, Madden T, Newman RA, et al.: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer [abstract]. J Clin Onco1 1996, 14:2713–2721.Google Scholar
  30. 30.
    Bellot R, Robert J, Dieras V, et al.: Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol [abstract]. Proc Am Soc Clin Onco1 1998, 17:221.Google Scholar
  31. 31.
    Genentech: Herceptin Investigator’s Brochure. South San Francisco: Genentech; 1999.Google Scholar
  32. 32.
    Speyer J, Green M, Kramer E, et al.: Protective effect of the bispiperazine ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Eng!JMed 1988, 319:745–752.CrossRefGoogle Scholar
  33. 33.
    Swain S, Whaley F, Gerber M, et al.: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Onco1 1997, 15:1333–1340.Google Scholar
  34. 34.
    Lopez M, Vici P, Lauro LD, et al.: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Onco1 1998, 16:1–7.Google Scholar
  35. 35.
    Sorensen B, Bastholt L, Mirza M, et al.: The cardioprotector ADR529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. Cancer Chemother Pharmaco1 1994, 34:439–443.CrossRefGoogle Scholar
  36. 36.
    Legha S, Benjamin R, Mackay B, et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982, 96:133–139.PubMedCrossRefGoogle Scholar
  37. 37.
    Torti F, Bristow M, Howes A, et al.: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983, 99:745–749.PubMedCrossRefGoogle Scholar
  38. 38.
    Berry G, Billingham M, Alderman E, et al.: Reduced cardiotoxicity of Doxil in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin [abstract]. Proc Annu Meet Am Soc Clin Onco1 1996, 15:A843.Google Scholar
  39. 39.
    Gottdeiner J, Appelbaum F, Ferrans V, et al.: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981, 141:758–763.CrossRefGoogle Scholar
  40. 40.
    Cazin B, Gorin N, Laporte J, et al.: Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer 1986, 57:2061–2069.PubMedCrossRefGoogle Scholar
  41. 41.
    Stewart JR FL: Radiation-induced heart disease: an update. Cardiovasc Dis 1984, 27:27–35.Google Scholar
  42. 42.
    Freeman N, Costanza M: 5-Fluorouracil associated carciotoxicity. Cancer 1988, 61:36–45.PubMedCrossRefGoogle Scholar
  43. 43.
    Weidmann B, Teipel A, Niederle N: The syndrome of 5-Fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1994, 73:2001–2002.PubMedCrossRefGoogle Scholar
  44. 44.
    Forni MD, Malet-Martino M, Jaillais P, et al.: Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Onco1 1992, 10:1795–801.Google Scholar
  45. 45.
    Akhtar S, Salim K, Bano Z: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993, 50:441–444.PubMedCrossRefGoogle Scholar
  46. 46.
    Keung YK, Lau S, Elkayam U, et al.: Cardiac arrythmia after infusion of cryopreserved stem cells. Bone Marrow Transplantation 1994, 14:363–367.PubMedGoogle Scholar
  47. 47.
    Lopez-Jimenez J, Munoz A, Hdez-Madrid A, et al.: Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. Bone Marrow Transplantation 1994, 13:789–793.PubMedGoogle Scholar
  48. 48.
    Rowinkky E, McGuire W, Guarnieri T, et al.: Cardiac disturbances during the administration of Taxol. J Clin Onco1 1991, 9:1704–1712.Google Scholar
  49. 49.
    Arbuck S, Strauss H, Rowinksy E, et al: A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993, 15:117–130.PubMedGoogle Scholar
  50. 50.
    Bristow M, Thompson P, Martin R, et al.: Early anthracycline cardiotoxicity. AmJMed 1978, 65:823–832.Google Scholar
  51. 51.
    Lawmore-Luria H, Kohn K, Pasternack R: Radiation heart disease. J Cardiovasc Med 1993, 8:113–125.Google Scholar
  52. 52.
    Tarbell N, Thompson L, Mauch P: Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990, 18:275–282.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Matthew Volm
  • Howard Hochster

There are no affiliations available

Personalised recommendations